Last reviewed · How we verify
Colchicine (for 1 month)
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators. Used for Acute gout flare prophylaxis and treatment, Familial Mediterranean fever, Pericarditis (post-myocardial infarction or recurrent).
At a glance
| Generic name | Colchicine (for 1 month) |
|---|---|
| Sponsor | Azienda Sanitaria Locale 3, Torino |
| Drug class | Microtubule inhibitor / Anti-inflammatory agent |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Colchicine binds to β-tubulin and prevents microtubule assembly, which disrupts cell division and inflammatory cell movement. This mechanism reduces the recruitment of neutrophils and other immune cells to sites of inflammation, and decreases the production of pro-inflammatory cytokines such as IL-1β and TNF-α. The drug has been used for decades in gout and is now being investigated for broader anti-inflammatory indications.
Approved indications
- Acute gout flare prophylaxis and treatment
- Familial Mediterranean fever
- Pericarditis (post-myocardial infarction or recurrent)
- Cardiovascular inflammation (investigational)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Myopathy
- Peripheral neuropathy
Key clinical trials
- Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome (NA)
- Design and Rationale of the COLT Study (PHASE3)
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study (PHASE4)
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (PHASE4)
- A Randomized Multicenter Study for Isolated Skin Vasculitis (PHASE2)
- COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction (PHASE2, PHASE3)
- Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise (NA)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine (for 1 month) CI brief — competitive landscape report
- Colchicine (for 1 month) updates RSS · CI watch RSS
- Azienda Sanitaria Locale 3, Torino portfolio CI